The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients

Annals of Pharmacotherapy

Volumn 31, Issue 4, 1997, Pages 489-491

  Southworth, Mary Ross ^a,b   Mauro, Vincent F ^a,c  

^a UNIVERSITY OF TOLEDO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ARTERY GRAFT; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; DRUG USE; GRAFT PATENCY; HEART TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; RHABDOMYOLYSIS;

EID: 0030910648     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100417     Document Type: Article

References (32)

1. Schroeder JS. Cardiac transplantation. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw Hill, 1994:1009-11.
2. Gao S-Z, Schroeder JS, Alderman EL, Hunt SA, Silverman JF, Wielderhold V, et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 1987;76(suppl V):V-56-61.
3. Billingman ME. Cardiac transplant atherosclerosis. Transplant Proc 1987;19:19-25.
4. Schroeder JS, Gao S-Z. Calcium blockers and atherosclerosis: lessons from the Stanford transplant coronary artery disease/diltiazem trial. Can J Cardiol 1995;11:710-5.
5. Sharpies LD, Caine N, Mullins P, Scott JP, Solis E, English TAH, et al. Risk factor analysis for the major hazards following heart transplantation - rejection, infection, and coronary occlusive disease. Transplantation 1991;52:244-52.
6. Eich D, Thompson JA, Ko D, Hastillo A, Lower R, Katz S, et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant 1991;10:45-9.
7. Gao S-Z, Schroeder JS, Hunt S, Stinson EB. Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol 1988;62:876-81.
8. Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation. N Engl J Med 1991;324:1791-4.
9. Gao S-Z, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988;12:334-40.
10. McKenney JM, Hawkins DW, eds, Lipid disorders: pathogenesis, lipid metabolism, detection, and evaluation. In: Handbook on the management of lipid disorders. National Pharmacy Cholesterol Council, 1995:12-57.
11. Hess ML, Hastillo A, Mohanakumar T, Cowley MJ, Vetrovac G, Szenpetery S, et al. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 1983;68 (suppl II):II-94-101.
12. Petrossian GA, Nichols AB, Marboe CC, Sciacca R, Rose EA, Smith CR, et al. Relation between survival and development of coronary artery disease and anti-HLA antibodies after cardiac transplantation. Circulation 1989;80(suppl III):III-122-5.
13. Grattan MT, Moreno-Cabral CE, Starnes VA, Over PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis, JAMA 1989;261:3651-6.
14. Stamler JS, Vaughan DE, Rudd MA, Mudge GH, Kirshenbaum J, Young P, et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1988;62:1268-72.
15. Keogh A, Simons L, Spratt P, Esmore D, Chang V, Hickie J, et al. Hyperlipidemia after heart transplantation. J Heart Transplant 1988;7:171-5.
16. Kubo SH, Peters JR, Knutson KR, Hertz MI, Olivari MT, Bolman RM, et al. Factors influencing the development of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1992;70:520-6.
17. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995;29:743-59.
18. Wenke K, Meiser B, Thiery J, Arndtz N, von Scheidt W, Reichart B. Is reduction of graft vessel disease by maximal treatment of hypercholesterolemia after heart transplantation possible? Transplant Proc 1995;27:1954-5.
19. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
20. Kruezer J, Bader J, Jahn L, Hautmann M, Kubler W, Von Hodenberg E. Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991;90:203-9.
21. Cutts JL, Scallen TJ, Watson J, Banhurst AD. Role of mevalonic acid in the regulation of natural kill cell cytotoxicity. J Cell Physiol 1989;139:550-7.
22. Cutts JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990;145:244-52.
23. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastalin (letter). N Engl J Med 1988;318:46-7.
24. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter). N Engl J Med 1988;318:47-8.
25. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 1988;260:239-41.
26. Kobashigawa JA, Murphy FL, Stevenson LW, Moriguchi JD, Kawata N, Kamjoo P, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990;82(suppl IV):IV-281-3.
27. Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993;25:2732-4.
28. Kuo PC, Kirshenbaum JM, Gordon J, Laffel G, Young P, DiSesa VJ, et al. Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol 1989;64:631-5.
29. Anguita M, Alonso-Pulpon L, Arizon JM, Cavero MA, Valles F, Segovia J, et al. Comparison of the effectiveness of lovastatin therapy for hypercholesterolemia after heart transplantation between patients with and without pretransplant atherosclerotic coronary artery disease. Am J Cardiol 1994;74:776-9.
30. Barbir M, Rose M, Kushwaha S, Akl S, Mitchell A, Yacoub M. Lowdose simvastatin for the treatment of hypercholesterolemia in recipients of cardiac transplantation. Int J Cardiol 1991;33:241-6.
31. Campana C, Iacona I, Regazzi MB, Gavazzi A, Perani G, Raddato V, et al. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995;29:235-9.
32. Vanhaecke J, Van Cleemput J, Van Lierde J, Daenen W, De Geest H. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994;58:42-5.